Skip to main content
OpenTrials
Completed

NCT Number: NCT05012163

Lottery Incentive Nudges to Increase Influenza Vaccinations

In the current study, the study team will explore whether small incentives are effective at promoting flu vaccine uptake. The study is designed to compare the relative efficacy of incentives of equal perceived expected value (EV) or equal implementation costs, to assess whether people are more likely to get vaccinated in response to lotteries with very high payoffs than to small certain cash payout or slightly higher-probability, more moderate payoffs. In particular, given the potential appeal of official state lottery tickets, one study arm will receive a Pennsylvania scratch-off lottery ticket for getting a flu vaccine. A primary hypothesis is that lotteries will outperform simple reminders (encouraging respondents to get the flu shot at their upcoming appointment) and the standard of care, representing the ambient healthcare system and public health campaigns to increase vaccination.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Geisinger Clinic

Danville, Pennsylvania, 17822, United States

About this study

During the 2021-22 flu season, the study team will contact Geisinger patients who have a primary care or specialist appointment scheduled during flu season and encourage them to get a flu shot.

Patients will be randomized into 4 to 9 study arms, depending on a sample size projection completed in August 2021. Arms will test the relative efficacy of a variety of small monetary incentives on flu shot uptake. Incentives may include (a) a $1 Pennsylvania scratch-off lottery ticket (with top prize of $5,000), (b) $1 in cash, (c) entry into a raffle for $5,000 absent upfront odds, (d) entry into a raffle for $5,000, with 1-in-5,000 odds of winning, (d) entry into a raffle for $50, with 1-in-50 odds of winning, and (e) entry into a raffle for $500, with 1-in-500 odds of winning. There will be one no-contact control arm and at least 1 reminder control arm (with additional control arms added given sufficient sample size and additional message versions to be tested).

Included in the study will be current Geisinger patients 18+ years of age with no contraindications for flu vaccine who have an appointment scheduled during the study period with a provider who can administer the vaccine. The primary study outcomes will be the rates of flu vaccination and flu diagnosis during the 2021-22 season by targeted patients.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Aged 18+
  • Pennsylvania mailing address listed
  • Geisinger primary care provider (PCP) assigned
  • Upcoming appointment with PCP or select specialist who stocks and can administer the vaccine during the study period

Exclusion criteria

  • Has opted out of receiving messages from Geisinger on all modalities being tested

Treatment and study plan

Reminder

Behavioral

Letter, short message service (SMS) text, phone, and/or email

Financial incentive

Behavioral

Letter, SMS, phone, and/or email

Lottery

Behavioral

Letter, SMS, phone, and/or email

Primary outcomes

  1. Flu Vaccination at Appointment

    Time frame: 3 days after patient is randomized

    Received flu vaccination at relevant PCP or specialty appointment.

Secondary outcomes

  1. Flu Vaccination Within 7 Days

    Time frame: Within 7 days of when patient is randomized

    Received flu vaccination

  2. Flu Diagnosis

    Time frame: During the 2021-22 flu season (Up to 8 months, from the time the patient is randomized through April 30, 2022)

    Received a "high confidence flu" diagnosis (with positive polymerase chain reaction [PCR]/antigen/molecular test) and/or "likely flu" diagnosis (as assessed via International Classification of Disease [ICD] codes or Tamiflu administration or positive PCR/antigen/molecular test)

    Note that "likely flu" is a superset of the "high confidence flu" diagnoses.

  3. Flu Complications

    Time frame: During the 2021-22 flu season (Up to 11 months, from the time the patient is randomized through July 31, 2022)

    Diagnosed with flu-related complications

Other outcomes

  1. Flu Vaccination (Among Subject Cohabitants) Within 28 Days

    Time frame: Within 28 days of when the study subject is randomized

    Cohabitant of study subject received flu vaccination

  2. Flu Vaccination at Appointment by Gender

    Time frame: 3 days after the patient is randomized.

    Received flu vaccination at relevant PCP or specialty appointment.

  3. Flu Vaccination at Appointment by Race

    Time frame: 3 days after the patient is randomized.

    Received flu vaccination at relevant PCP or specialty appointment.

  4. Flu Vaccination at Appointment by Ethnicity

    Time frame: 3 days after the patient is randomized.

    Received flu vaccination at relevant PCP or specialty appointment.

Sponsors and collaborators

Lead sponsor

National Bureau of Economic Research, Inc.

Other

Collaborators

  • Geisinger Clinic
  • Massachusetts Institute of Technology
  • National Institute on Aging (NIA)

Registry information

Important dates

Study start
2021
Primary completion
2021
Study completion
2022
First posted
Aug 19, 2021
Registry last updated
Dec 30, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.